リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「SARS-CoV-2 Research Using Human Pluripotent Stem Cells and Organoids」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

SARS-CoV-2 Research Using Human Pluripotent Stem Cells and Organoids

Deguchi, Sayaka Serrano-Aroca, Ángel Tambuwala, Murtaza M. Uhal, Bruce D. Brufsky, Adam M. Takayama, Kazuo 京都大学 DOI:10.1002/sctm.21-0183

2021.11

概要

Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798): 270-273.

2. Jiang R-D, Liu M-Q, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020;182(1):50-58.e58.

3. Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327-1335.

4. Muñoz-Fontela C, Dowling WE, Funnell SG, et al. Animal models for COVID-19. Nature. 2020;586(7830):509-515.

5. Artegiani B, Clevers H. Use and application of 3D-organoid technol- ogy. Hum Mol Genet. 2018;27(R2):R99-R107.

6. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131 (5):861-872.

7. Takayama K. In vitro and animal models for SARS-CoV-2 research. Trends Pharmacol Sci. 2020;41(8):513-517.

8. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New Eng J Med. 2020;382(8):727-733.

9. Guan W-j, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Eng J Med. 2020;382(18):1708-1720.

10. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.

11. Katsura H, Sontake V, Tata A, et al. Human lung stem cell-based alveolospheres provide insights into SARS-CoV-2-mediated inter- feron responses and pneumocyte dysfunction. Cell Stem Cell. 2020;27 (6):890-904.e898.

12. Huang J, Hume AJ, Abo KM, et al. SARS-CoV-2 infection of pluripo- tent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell. 2020;27(6): 962-973.e967.

13. Mulay A, Konda B, Garcia G Jr, et al. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. Cell Rep. 2021;35(5):109055.

14. Pei R, Feng J, Zhang Y, et al. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection. Protein Cell. 2020.

15. Lamers MM, Mykytyn AZ, Breugem TI, et al. Human airway cells pre- vent SARS-CoV-2 multibasic cleavage site cell culture adaptation. Elife. 2021;10:e66815.

16. Li Y, Renner DM, Comar CE, et al. SARS-CoV-2 induces double- stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes. Proc Natl Acad Sci. 2021; 118(16):e2022643118.

17. Yin X, Riva L, Pu Y, et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep. 2021;34(2):108628.

18. Lamers MM, van der Vaart J, Knoops K, et al. An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. EMBO J. 2021;40(5):e105912.

19. Li F, Han M, Dai P, et al. Distinct mechanisms for TMPRSS2 expres- sion explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021;12(1):1-14.

20. Youk J, Kim T, Evans KV, et al. Three-dimensional human alveolar stem cell culture models reveal infection response to SARS-CoV-2. Cell Stem Cell. 2020;27(6):905-919.e910.

21. Han Y, Duan X, Yang L, et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021;589(7841):270-275.

22. Suzuki T, Ito Y, Sakai Y et al. Generation of human bronchial organoids for SARS-CoV-2 research. BioRxiv 2020.

23. Bojkova D, Wagner JU, Shumliakivska M, et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc Res. 2020;116(14):2207-2215.

24. Perez-Bermejo JA, Kang S, Rockwood SJ, et al. SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. Sci Transl Med. 2021;13:eabf7872.

25. Garcia G Jr, Sharma A, Ramaiah A, et al. Antiviral drug screen iden- tifies DNA-damage response inhibitor as potent blocker of SARS- CoV-2 replication. Cell Rep. 2021;35(1):108940.

26. Marchiano S, Hsiang T-Y, Khanna A, et al. SARS-CoV-2 infects human pluripotent stem cell-derived cardiomyocytes, impairing electrical and mechanical function. Stem Cell Rep. 2021;16(3):478-492.

27. Mills RJ, Humphrey SJ, Fortuna PR, et al. BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell. 2021;184(8):2167-2182.e2122.

28. Yang L, Han Y, Nilsson-Payant BE, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27(1): 125-136.e127.

29. Krüger J, Groß R, Conzelmann C, et al. Drug inhibition of SARS- CoV-2 replication in human pluripotent stem cell–derived intestinal organoids. Cell Mol Gastroenterol Hepatol. 2021;11(4):935-948.

30. Mithal A, Hume AJ, Lindstrom-Vautrin J, et al. Human pluripotent stem cell-derived intestinal organoids model SARS-CoV-2 infection revealing a common epithelial inflammatory response. Stem Cell Rep. 2021;16(4):940-953.

31. Wysocki J, Ye M, Hassler L, et al. A novel soluble ACE2 variant with prolonged duration of action neutralizes SARS-CoV-2 infec- tion in human kidney organoids. J Am Soc Nephrol. 2021;32(4): 795-803.

32. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infec- tions in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905-913.e907.

33. Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218(3):e20202135.

34. Pellegrini L, Albecka A, Mallery DL, et al. SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell. 2020;27(6):951-961.e955.

35. Jacob F, Pather SR, Huang W-K, et al. Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neu- rotropism predominates in choroid plexus epithelium. Cell Stem Cell. 2020;27(6):937-950.e939.

36. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-810.

37. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospital- ized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690.

38. Han C, Duan C, Zhang S, et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. 2020;115:916-923.

39. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treat- ment of Covid-19. New Eng J Med. 2020;383(19):1813-1826.

40. Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonu- cleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 trans- mission in ferrets. Nat Microbiol. 2021;6(1):11-18.

41. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e278.

42. Jin J-M, Bai P, He W, et al. Gender differences in patients with COVID- 19: focus on severity and mortality. Front Public Health. 2020;8:152.

43. Zhu L, She Z-G, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 dia- betes. Cell Metab. 2020;31(6):1068-1077.e1063.

44. Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospital- ized with COVID-19. Circ Res. 2020;126(12):1671-1681.

45. Millett GA, Jones AT, Benkeser D, et al. Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol. 2020;47:37-44.

46. Severe Covid-19 GWAS Group. Genomewide association study of severe Covid-19 with respiratory failure. New Eng J Med. 2020;383 (16):1522-1534.

47. Sano E, Deguchi S, Sakamoto A, et al. Modeling SARS-CoV-2 infec- tion and its individual differences with ACE2-expressing human iPS cells. iScience. 2021;24(5):102428.

48. Dobrindt K, Hoagland DA, Seah C, et al. Common genetic variation in humans impacts in vitro susceptibility to SARS-CoV-2 infection. Stem Cell Rep. 2021;16(3):505-518.

49. Wang C, Zhang M, Garcia G Jr, et al. ApoE-isoform-dependent SARS- CoV-2 neurotropism and cellular response. Cell Stem Cell. 2021;28(2): 331-342.e335.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る